ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 035,65
0,54%
Dow Jones
38 686,32
0,00%
DAX
18 677,61
1,05%
Brent Oil
80,775
-0,04%
Bitcoin
69 626,72
2,77%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) Actualités

RPRX

Royalty Pharma (RPRX)

Royalty Pharma PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RPRX
DateHeureSourceTitreSymboleSociété
03/06/202414h39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RPRXRoyalty Pharma PLC
29/05/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
28/05/202413h10GlobeNewswire Inc.Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionNASDAQ:RPRXRoyalty Pharma PLC
22/05/202422h10GlobeNewswire Inc.Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
22/05/202422h00GlobeNewswire Inc.Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
16/05/202423h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
13/05/202414h15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
09/05/202415h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
09/05/202413h00GlobeNewswire Inc.Royalty Pharma Reports First Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
09/05/202412h45GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Sanofi’s FrexalimabNASDAQ:RPRXRoyalty Pharma PLC
19/04/202414h15GlobeNewswire Inc.Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/04/202414h15GlobeNewswire Inc.Royalty Pharma Declares Second Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
28/02/202422h15GlobeNewswire Inc.Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:RPRXRoyalty Pharma PLC
15/02/202415h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RPRXRoyalty Pharma PLC
15/02/202413h30GlobeNewswire Inc.Royalty Pharma Reports Q4 and Full Year 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
30/01/202422h15GlobeNewswire Inc.Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024NASDAQ:RPRXRoyalty Pharma PLC
19/01/202414h15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
08/01/202413h00GlobeNewswire Inc.Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/01/202422h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RPRXRoyalty Pharma PLC
27/11/202322h15GlobeNewswire Inc.Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:RPRXRoyalty Pharma PLC
16/11/202323h13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RPRXRoyalty Pharma PLC
13/11/202314h10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNASDAQ:RPRXRoyalty Pharma PLC
13/11/202314h00Business WireTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI ProgramNASDAQ:RPRXRoyalty Pharma PLC
08/11/202313h00GlobeNewswire Inc.Royalty Pharma Reports Third Quarter 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
19/10/202313h59GlobeNewswire Inc.Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on EvrysdiNASDAQ:RPRXRoyalty Pharma PLC
16/10/202322h15GlobeNewswire Inc.Royalty Pharma Declares Fourth Quarter 2023 DividendNASDAQ:RPRXRoyalty Pharma PLC
11/10/202322h15GlobeNewswire Inc.Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023NASDAQ:RPRXRoyalty Pharma PLC
21/09/202314h25GlobeNewswire Inc.Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerNASDAQ:RPRXRoyalty Pharma PLC
05/09/202322h15GlobeNewswire Inc.Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
05/09/202322h01GlobeNewswire Inc.Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:RPRX

Dernières Valeurs Consultées

BIT
EMAAA
ETF
BIT
S28226
Societe Generale Effekten
NASDAQ
TRNC
tronc, Inc.
TSXV
LWI.H
NYSE
UMH-C
UMH Properties
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés